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Objective: Evaluation whether biomarkers of joint damage are sensitive to change shortly after a joint
bleed in hemophilia patients and in a canine model of blood-induced joint damage.
Methods: Blood and urine samples were collected from 10 hemophilia patients after they reported a joint
bleed: within 2 days, after 3e5 days, and 12e14 days. Additionally, 90 days after the bleed a blood and
urine sample was taken and considered to represent baseline condition. Commercial serum and urine
biomarker assays were performed: urinary C-terminal telopeptide of type II collagen (uCTX-II), serum
cartilage oligomeric matrix protein (sCOMP), serum cartilage cleavage product C1,2C, and serum chon-
droitin sulfate 846 (sCS846).
The same panel of biomarkers was explored in dogs (n ¼ 7) after induction of a ﬁrst joint bleed by intra-
articular blood injections. Biosamples were collected at baseline, day 2, 1 and 2 weeks later.
Results: In hemophilia patients, levels of uCTX-II and sCS846 increased 5 days after joint bleeding when
compared with baseline (þ52%; P ¼ 0.021 and þ14%; P ¼ 0.011, respectively). In dogs, uCTX-II increased
statistically signiﬁcant from day 2 to day 7 (from 75% to 155% of baseline; P ¼ 0.018), and sCOMP from
baseline to day 2 (þ46%; P ¼ 0.028).
Conclusions: This study demonstrates that biochemical markers of joint tissue damage increase shortly
after a single joint bleed, both in humans with established hemophilic arthropathy (HA) and in an animal
model of joint damage upon a ﬁrst joint bleed. Biomarkers might be useful in monitoring the impact of a
joint bleed and in evaluation of treatment of such bleeds.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Progressive damage of cartilage and bone, and synovial
inﬂammation are the main characteristics of different joint dis-
eases, either primarily degeneration-mediated such as osteoar-
thritis (OA), primarily inﬂammation-mediated such as rheumatoid
arthritis (RA), or a combination of both processes as seen in.F.D. van Vulpen, Department
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ternational. Published by Elsevier Lhemophilic arthropathy (HA)1. Developing diagnostic tools to
identify patients at high risk of developing or progression of joint
damage early in the disease remains an important, yet challenging
aspect. Assessments are mainly based on imaging techniques,
involving plain radiography, ultrasonography (US), and magnetic
resonance imaging (MRI)2e4. Each technique has its own advan-
tages and limitations, regarding availability, accuracy, costs, ex-
amination time, and scoring systems.
An alternative approach could be offered by the use of serum or
urine biochemical markers of joint tissue turnover5. They have the
potential to reﬂect dynamic changes in joint tissue turnover,
whereas imaging techniques provide information as a result of
these dynamic processes over time. As such these biochemical
markers might be of use as diagnostic tool to treat patients more
adequately and to monitor disease progression and treatment ef-
ﬁcacy more closely. Unfortunately, despite extensive research, at
present none of the biochemical markers of joint damage istd. All rights reserved.
L.F.D. van Vulpen et al. / Osteoarthritis and Cartilage 23 (2015) 63e6964sufﬁciently valuable for diagnosis or prognosis of joint diseases at
the level of an individual patient6.
Investigating biochemical markers in diseases like OA and RA is
challenging as associations might be obscured by the presence of
presumed but not yet fully characterized phenotypic differences
within the OA7 and RA populations8. Patients being at different
stages of the disease, the involvement of single to multiple joints,
aggressive treatment, and a systemic inﬂammatory component in
case of RA, may inﬂuence biomarker metabolism signiﬁcantly9.
Hence, it is attractive to investigate biochemical markers in a dis-
ease model with a clear trigger for damage progression as is the
case in hemophilia at the moment of a joint bleed.
In hemophilia blood-induced joint damage is still the most
important cause of morbidity, despite the increased use of pro-
phylactic infusions of clotting factor concentrates10. It has been
demonstrated clinically and experimentally, that recurrent bleeds
but also a limited number or even a single joint bleed cause dam-
age1,11e14. A joint bleed initiates a combined cascade of inﬂamma-
tory and degenerative processes causing a relatively fast
progressive arthropathy. Inﬂammation is restricted to the joint as
opposed to the chronic systemic inﬂammation seen in RA, and joint
damage is mainly restricted to the elbows, knees, and ankles, which
facilitates the quantiﬁcation of the extent of joint damage as
compared to diseases like OA and RA affecting alsomultiple smaller
joints like hands and spine.
The Pettersson scoring method, based on conventional radiog-
raphy of the main involved joints (elbows, knees, and ankles), is a
well-validated scoring method to assess joint damage in hemo-
philia15,16. A good cross-sectional correlation is demonstrated be-
tween biochemical markers of joint damage and radiographic joint
damage for urinary C-terminal telopeptide of type II collagen
(uCTX-II), serum cartilage oligmeric matrix protein (sCOMP), serum
cartilage cleavage product C1,2C (sC1,2C), and serum chondroitin
sulfate 846 (sCS846)17.
To date, no data are available on the response of biochemical
markers to a joint bleed. The purpose of this explorative study
was to investigate whether these biochemical markers are sen-
sitive to change upon blood-induced joint tissue damage in pa-
tients with hemophilia with established HA and in a canine




Patients with moderate or severe hemophilia A or B (18 years,
n ¼ 10) reporting a joint bleed in their elbow, knee or ankle were
included. Blood and urine samples were prospectively collected at
three successive time-points: within 2 days, between day 3 and 5,
and between 12 and 14 days after the bleed. Additionally at about
90 days after the reported joint bleed a blood and urine sample was
taken, considered to represent baseline. Exclusion criteria were the
presence of human immunodeﬁciency virus infection, the presence
of antibodies that neutralize clotting factors, or a body mass index
>30 kg/m2.
The studywas undertaken in accordancewith the Declaration of
Helsinki, and was approved by the Medical Ethical Review Board.
Written informed consent was obtained from all study participants.
Human serum and urine sampling
Ten milliliters of blood was collected into Vacutainer tubes
(Becton Dickinson, Oxford, UK). A total of eight IU of recombinant
clotting factor concentrate (factor VIII or factor IX, as appropriate)was added. Blood was kept at room temperature for at least 1 h to
ensure proper coagulation. Thereafter, samples were centrifuged at
1500g for 10 min. Serum aliquots were obtained and stored
at 80C until use. Urine samples were kept at 4C for a maximum
of 8 h, and then aliquoted and stored at 80C. Non-fasted samples
were collected between 8:00 A.M. and 12:00 A.M.
Canine in vivo experiments
Seven skeletally mature Beagle dogs (3/4 male/female; mean
age 2.1 ± 0.1 years; weight 12.2 ± 0.4 kg) were obtained from the
animal laboratory of the Utrecht University, The Netherlands, and
housed in groups of 2e3 dogs. They were let out at least 2 h daily,
and fed a standard commercial diet with water ad libitum. The
Utrecht University Animal Experiments Committee approved the
study protocol.
In all dogs a joint bleed was mimicked by injecting 1.8 ± 0.1 mL
freshly collected (vena puncture) autologous blood intra-articularly
in the left knee. These procedures were performed under short-
term anesthesia (Dormitor/Antisedan). Accuracy of the injection
was checked randomly by placing a second needle at the other side
of the joint. A blood ﬂow from the injected joint was demonstrated
in all cases, indicating complete ﬁlling of the joint with blood. After
removal of the needles, pressure was put on the puncture holes
until the bleed stopped, preventing leakage of blood outside the
joint cavity.
Four blood injections in the left knee were given in four suc-
cessive days, because of the rapid clearance of blood from the
canine joint in contrast to humans14. As previously shown, this
results in a period of at least 4 days continuous blood exposurewith
at least 20% v/v blood and leads to mild progressive cartilage
damage and synovitis over time mimicking HA13,14.
Canine serum and urine sampling
Serum and urine samples were collected from each dog before
the intra-articular blood injections (baseline), halfway the injec-
tion period (day 1e2), one (day 7) and 2 weeks (day 14) later. To
validate the surrogate baseline values used in the human study
(obtained at day 90 post bleeding), biosamples were also obtained
at week 13 and compared with baseline. All samples were ob-
tained in the morning, but were non-fasted, similar to the human
clinical situation. Ten milliliters of blood was collected into
Vacutainer tubes (Becton Dickinson) and allowed to coagulate for
at least 1 h at room temperature. Subsequently samples were
centrifuged at 1500g for 10 min, aliquoted and stored at 80C
until the biomarker analysis was performed. Urine was obtained
by catheterization and kept at 4C for a maximum of 8 h, and then
aliquoted and stored at 80C.
Biomarker assays
All biomarkers were measured in duplicate using standard
enzyme-linked immunosorbent assay (ELISA) kits according to the
manufacturer's instructions. All samples for any single patient or
dog were tested on the same plate to avoid inter-plate variance,
with all plates purchased from the same batches. Urine samples
were assessed for the level of uCTX-II (human samples CartiLaps;
canine samples Pre-Clinical Cartilaps; both from IDS Ltd., Boldon,
UK) and these levels were corrected for creatinine levels (Cayman
Chemicals, Ann Arbor, MI, USA). In serum samples sCOMP (speciﬁc
kit for human or canine COMP, both from Novatein Biosciences,
Woburn, MA, USA), sC1,2C, and sCS846 (kits with broad cross-
reactivity including human and dog, both from IBEX, Montreal,
Quebec, Canada) were determined.
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Data distribution was assessed using the ShapiroeWilk tests for
normality. None of the biomarkers was normally distributed, and
this could not be achieved by natural log transformation for all
biomarkers. Accordingly, non-parametric tests for related samples
(Friedman's test followed by a post hoc Wilcoxon signed rank test)
were used. All statistical analyses were performed using absolute
data. Values are expressed as percentage compared to baseline and
depicted as individual values together with the median.
Statistical calculations were performed with SPSS version 20.0
(SPSS Inc., Chicago, IL, USA). P values less than 0.05 (two-sided)
were considered statistically signiﬁcant.
Results
Patient characteristics
The study population consisted of six patients with severe he-
mophilia A, three patients with moderate hemophilia A, and one
patient with severe hemophilia B. The age at time of the joint bleed
ranged from 18 years to 71 years (mean 53 years, SD 18 years).
Three patients received clotting factor replacement therapy as
prophylaxis and seven received treatment on demand. Three pa-
tients reported a joint bleed in the knee, six in the elbow, and one
patient had an ankle joint bleed. There was a wide variation in the
amount of clotting factor consumption (300e6000 IU/kg/year),
average number of joint bleeds per year (0e20), number of affected
joints (1e6) and total Pettersson score (5e68). Two patients had
undergone joint replacement in the past.
uCTX-II and sCS846 change upon a joint bleed in hemophilia
patients
Baseline levels of the biomarkers could not be determined
previous to a joint bleed, since the occurrence of a joint bleed could
not be predicted. Therefore samples collected around 90 days after
the joint bleed were considered baseline. Table I shows the median
(25e75% percentile) of the absolute biomarker concentrations at
each time point. Additionally, data are depicted as percentage
compared to baseline (100%) in Fig. 1 because biomarker baseline
values varied widely between patients. A clear correlation between
the Pettersson score and baseline values was lacking in our study
(data not shown).
uCTX-II levels (Table I) changed statistically signiﬁcantly over time
(P ¼ 0.016). Within 2 days after the bleed, no change in uCTX-II
concentration was seen compared to baseline levels (þ22%;
P ¼ 0.878; Fig. 1(A)). At day 5, a signiﬁcant increase was detected
when compared to baseline (þ52%; P ¼ 0.021). This increase was
approaching statistical signiﬁcance when compared to the uCTX-II
concentration measured within 2 days after the joint bleed
(P¼ 0.086). The concentrations droppedat 14days to almost baseline
levels (þ16% compared to baseline value; P ¼ 0.037), which was a
statistically signiﬁcant decrease compared to day 5 (P ¼ 0.008).Table I
Change in biomarkers after a joint bleed in hemophilia patients
Biomarker Baseline 2 days
uCTX-II (mg/mmol creatinine) 0.38 (0.20e0.60) 0.30 (0.23e1.08
sCOMP (ng/mL) 89.4 (76.0e92.5) 85.5 (78.1e100
sC1,2C (ng/mL) 530 (489e682) 480 (449e640
sCS846 (ng/mL) 202 (136e252) 196 (144e268
Absolute values of biomarkers are presented as median (25e75% percentile). Statisticall
* Friedman's test.Also sCS846 showed a signiﬁcant change over time (Table I;
P¼ 0.004). Immediately after the bleed, the concentrations were still
comparable to baseline (þ5%; P ¼ 0.575). At day 5, an increase in
sCS846 concentrationswas observed [Fig.1(D)], bothwhencompared
to baseline levels (þ14%; P ¼ 0.011) as well as compared to the con-
centrations measured within 2 days (P ¼ 0.008). The concentrations
returned to baseline values at 14 days after the bleed (þ2% compared
to baseline value; P ¼ 0.285; compared to day 5; P ¼ 0.021).
Neither sCOMP nor sC1,2C showed signiﬁcant changes over time
(P ¼ 0.435 and P ¼ 0.316, respectively), although all patients
showed an increase in sCOMP at some point within the ﬁrst 5 days.
In four patients sCOMP levels increased already within 2 days after
the bleed when compared to baseline, whereas the other six pa-
tients showed an increase from day 2 to day 5. Such a trend was not
observed for sC1,2C.
uCTX-II and sCOMP change upon an experimentally induced joint
bleed in dogs
The observed changes in biochemical markers upon a joint
bleed in this small population of hemophilia patients with pre-
existing HA prompted us to conduct a study in a canine model of
blood-induced cartilage damage to have a more controlled set-up
in arthropathy naïve joints. In seven Beagle dogs changes in the
same panel of biomarkers were investigated upon an experimen-
tally induced joint bleed. For none of the biomarkers levels at week
13 were higher than at baseline suggesting normalization of the
biomarkers after such a time period post bleeding.
Absolute concentrations of biomarkers are shown in Table II and
in Fig. 2 data are depicted as percentage compared to baseline. The
concentrations of uCTX-II and sCOMP changed signiﬁcantly over
time (P ¼ 0.011 and P ¼ 0.004, respectively), whereas sC1,2C and
sCS846 showed no signiﬁcant changes over time (P ¼ 0.178 and
P ¼ 0.100, respectively; Table II).
The uCTX-II concentrations measured directly after the experi-
mentally induced joint bleed (day 1e2) were not statistically signif-
icantly different compared to levels at baseline (25%; P ¼ 0.398).
One week after the bleed, concentrations increased to 155% of
baseline levels (P¼ 0.176),whichwasa signiﬁcant increase compared
to levels at day 1e2 (P ¼ 0.018). One week later, uCTX-II concentra-
tions decreased slightly, but remained elevated compared to day 1e2
(P ¼ 0.063), and compared to baseline (þ42%; P ¼ 0.237).
sCOMP increased immediately after the bleed compared to
baseline (þ46%; P ¼ 0.028) and was still marginally but statistically
signiﬁcantly increased at day 7 (þ8%; P ¼ 0.043). Two weeks after
the bleed, the concentration of sCOMP decreased (P ¼ 0.018) to a
concentration slightly below baseline (8%; P ¼ 0.499).
Compared to baseline, sCS846 tended to decrease after the bleed
and stayed decreased,whereas sC1,2C did not showa clear tendency.
Discussion
The present study demonstrates that certain biochemical
markers of joint tissue turnover increase immediately upon a5 days 14 days P-value*
) 0.57 (0.38e1.10) 0.38 (0.31e0.74) 0.016
.1) 91.0 (80.4e96.3) 84.4 (78.9e96.2) 0.435
) 599 (506e674) 645 (517e709) 0.316
) 227 (158e283) 235 (138e261) 0.004
y signiﬁcant changes are in bold.
BC
A

















































































Fig. 1. Biomarkers of joint damage increase after an acute joint bleed in hemophilia patients. Blood and urine samples were collected after a joint bleed in 10 hemophilia patients.
uCTX-II (A) was measured in urine samples and corrected for creatinine levels. sCOMP (B), sC1,2C (C), and sCS846 (D) were measured in serum samples. All data are presented as
percentage compared to baseline. Friedman's test followed byWilcoxon signed rank test was performed on absolute data. Each gray line represents an individual patient, black lines
represent median values.
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damage (HA) as well as in damage naïve joints (a canine model for
blood-induced joint damage). This provides potential for the
further development and utilization of biochemical markers in
monitoring joint diseases such as OA, RA, and HA. Moreover, it
demonstrates that a canine model of blood-induced joint damage
might be of use in development and validation of new biomarkers.
In hemophilia patients, an increase in uCTX-II and sCS846 levels
was detected within a week after a joint bleed. Also a bleed in a
single large joint in a dog resulted in an elevation in uCTX-II and
sCOMP levels within a week after the bleed, but not in sCS846. This
demonstrates that it takes a few days before breakdownproducts of
joint tissue enter the circulation and can be measured in serum and
urine. Within 2 weeks the elevated levels had normalized,Table II
Change in biomarkers after an experimentally induced joint bleed in dogs
Biomarker Baseline 1e2 days
uCTX-II (mg/mmol creatinine) 1.97 (1.29e4.35) 2.34 (1.10e2.8
sCOMP (ng/mL) 31.5 (25.5e37.0) 46.0 (36.8e55.
sC1,2C (ng/mL) 903 (697e1159) 777 (613e998
sCS846 (ng/mL) 239 (219e317) 205 (169e288
Absolute values of biomarkers are presented as median (25e75% percentile). Statisticall
* Friedman's test.indicating that the original tissue destructive process is temporary.
As development of blood-induced joint damage is a progressive
process becoming evident a long time after a bleed18, the ﬁrst initial
peak of tissue damage is anticipated to be followed over time by an
intrinsic low level damage. This latter low level process can
apparently not be detected by the presently used biochemical
markers. This might add to the explanation why many of the
biochemical markers are only discriminative at group level6.
It is tempting to speculate that a change in biochemical markers
reﬂects the devastating effects of the bleed on a joint over time.
However, it remains to be investigated whether this initial increase
correlates with joint damage progression over time, aiding in
monitoring the impact of a joint bleed and in evaluation of treat-
ment efﬁcacy (e.g., clotting factor on demand, or anti-inﬂammatory8 days 14 days P-value*
6) 2.99 (2.61e4.21) 2.69 (1.90e3.47) 0.011
0) 38.2 (34.0e40.1) 31.9 (27.7e35.0) 0.004
) 1039 (546e1214) 935 (763e1267) 0.178
) 256 (162e312) 299 (147e312) 0.100
y signiﬁcant changes are in bold.
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Fig. 2. Biomarkers of joint damage increase in dogs after an experimentally induced joint bleed. In seven dogs, blood and urine samples were collected at four different time points
after an experimentally induced joint bleed. uCTX-II (A) was measured in urine samples and corrected for creatinine levels. sCOMP (B), sC1,2C (C), and sCS846 (D) were measured in
serum samples. All data are presented as percentage compared to baseline. Friedman's test followed by Wilcoxon signed rank test was performed on absolute data. Each gray line
represents a single dog, black lines represent median values.
L.F.D. van Vulpen et al. / Osteoarthritis and Cartilage 23 (2015) 63e69 67treatment19e21). It is important to extend the panel of biochemical
markers tested in HA, to gain a more detailed insight in the changes
in joint tissue turnover upon a joint bleed and to increase the
usefulness of such biochemical markers in clinical application.
Screening new biomarkers in a model of blood-induced joint
damagemight be helpful in developing a reliable biomarker of joint
damage for OA and RA. Despite all effort, at present none of the
investigated biochemical markers has sufﬁcient diagnostic or
prognostic value in these diseases9,22. Blood-induced damage is a
rather aggressive form of joint damagewith features of both OA and
RA11,23. Severely damaged joints are found at a much younger age
than in case of OA or RA24,25 and the pathologic processes are
initiated by a clear trigger. Clearly, it cannot be excluded that there
are pathways of joint damage (including cartilage, bone, and/or
synovium) speciﬁc for certain joint disease and not generic for all.
Of the screened biomarkers, uCTX-II showed the most evident
change as an increase was demonstrated to approximately 150% of
baseline in both the human and the canine study. CTX-II is seen as a
marker of articular cartilage degradation26, but is also suggested to
be involved in calciﬁed cartilage layer changes or even bone
metabolism27,28. The rapid elevation seen after a joint bleed is in
accordance with studies demonstrating release of CTX-II into sy-
novial ﬂuid within 1 week after joint injury in humans29 and a rise
in uCTX-II levels in two different canine OA models30.
sCOMP is a biomarker sensitive to mechanical loading of the
joint. Transient changes are demonstrated after physicalexercise31e33, even a 30-min walk can cause elevated levels of
sCOMP. The change is detected only within a few hours after ex-
ercise, but in marathon runners levels remained elevated for at
least 48 h33. In our canine study sCOMP rose almost immediately
after the joint bleed, whereas in hemophilia patients effects were
marginal and variable. A bleeding can be very painful, reducing
joint use signiﬁcantly and with that potentially reducing a rise in
sCOMP in hemophilia patients. In contrast, all animals quickly
regained joint loading after an experimental joint bleed. Another
possible confounder is a difference in duration of blood-exposure.
Patients were included in this study within 2 days after they re-
ported a joint bleed, therewith inducing already a variation of 48 h.
Duration of the bleed and response to clotting factor replacement
were not taken into account. Moreover, diurnal variation in
biomarker levels could be an interfering factor in the human study
compared to the canine study because for logistical reasons sam-
pling in humans was variable over the day. Also, pre-existing joint
damage in hemophilia patients might have inﬂuenced biomarker
levels as sCOMPwas shown to correlatewith the Pettersson score17.
In general, sCOMP might be more sensitive to change upon
different variables and as such less sensitive to change regarding
the actual joint tissue damage. However, this needs to be veriﬁed in
speciﬁcally designed studies.
Whereas sCS84634 increased signiﬁcantly in hemophilia pa-
tients, no change was detected in the canine model. This might be
due to the speciﬁcity of the used ELISA kit, which is optimized for
L.F.D. van Vulpen et al. / Osteoarthritis and Cartilage 23 (2015) 63e6968analyzing human samples and has cross-reactivity for different
species including dogs. The absence of pre-existing joint damage in
the canine study compared to an already increased proteoglycan
turnover at time of the joint bleed in hemophilia patients might
explain why a rise in CS846 was detected only in hemophilia pa-
tients. In a caninemodel of early OA induced by surgical transection
of the anterior cruciate ligament (ACL), serum levels of CS846 were
elevated already at 3 and 12 weeks compared to preoperative
levels35. ACL transection causes an unstable joint and therewith a
constant low level trigger compared to the temporary high impact
of a single large joint bleed. In our canine study CS846 levels even
tended to decrease after the joint bleed. These ﬁndings resemble
the decreased levels of CS846 in serum of patients with rapid
progressive RA compared to increased levels in patients with slow
progressive disease36, and the relatively lower synovial levels after
acute joint inﬂammation or joint injury compared to OA37.
The hemophilia population included in this study was rela-
tively small and heterogeneous with respect to age, pre-existing
joint damage, and annual bleeding frequency. Even despite this
heterogeneity, levels of biomarkers increased in response to a joint
bleed. On the other hand, it underlines the importance to relate
those levels to an individual baseline level. A limitation of the
human experiments is the use of surrogate baseline values
measured 90 days after the joint bleed. Obtaining baseline sam-
ples prior to the bleed was impossible as patients were enrolled at
the time of a joint bleed. The canine experiment demonstrated
that biomarker levels 13 weeks after the joint bleed dropped to (or
even below) baseline values. Nonetheless, the surrogate baseline
values might have been disturbed by recurrent (sub)clinical joint
bleeds experienced during follow up. The last bleed was reported
35 days before collection of biosamples for the surrogate baseline.
Since biomarker levels dropped already within 14 days after the
bleed, these in-between joint bleeds were considered irrelevant to
the baseline values.
In conclusion, this explorative study demonstrates that a rise in
biochemical markers of joint tissue turnover can be detected
directly after a single trigger on the joint, in this study a joint bleed
in patients with varying existing (hemophilic) arthropathy as well
as in a canine model of blood-induced joint damage without pre-
existing joint damage. This indicates biomarker evaluation still to
be a promising tool in detecting the destructive properties of joint
damage and possibly treatment-efﬁcacy. This study also conﬁrms
the changes in joint homeostasis induced by a single bleed,
stressing its joint destructive properties. Moreover, it emphasizes
the usefulness of blood-induced joint damage as a model to eval-
uate biochemical markers of joint damage.Author contributions
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